References
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381–9.
- Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681–90.
- Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, . Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2–3):123–36.
- Ahuja N, Lloyd AJ. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia. Ann Clin Psychiatry 2008;20(2):113–4.
- Barnas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry 2005;66(10):1339.
- Burke MJ, Lincoln J. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 2006;18(2):129–30.
- Glick ID, Duggal V, Hodulik C. Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol. 2006;26(1):101–3.
- Kapusta ND, Mossaheb N, Barnas C, Fischer P. Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry 2007;68(9): 1445–6.
- Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19(1):45–8.
- Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004;161(7):1308.
- Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004;37(Suppl 1):S4–11.
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261–76.
- Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, . Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164(9): 1404–10.
- Uzun S, Kozumplik O, Mimica N, Folnegovic-Smalc V. Aripiprazole: an overview of a novel antipsychotic. Psychiatr Danub 2005;17(1–2):67–75.
- Kuo J, Hwu HG. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 2008;31(3):173–5.
- Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, . Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berlin) 2000;152(2):174–80.
- Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, . Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69(5):720–31.
- Grohmann R, Strobel C, Ruther E, Dirschedl P, Helmchen H, Hippius H, . Adverse psychic reactions to psychotropic drugs – a report from the AMUP study. Pharmacopsychiatry 1993;26(3):84–93.
- Adan-Manes J, Garcia-Parajua P. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 2009;34(2):245–6.